Genomic Variant Prioritization AI Global Market Report 2026

The genomic variant prioritization artificial intelligence (AI) market size has grown exponentially in recent years. It will grow from $1.76 billion in 2025 to $2.22 billion in 2026 at a compound annual growth rate (CAGR) of 26.2%. The growth in the historic period can be attributed to growth of next generation sequencing adoption, increasing availability of genomic databases, rising prevalence of rare genetic disorders, expansion of bioinformatics research initiatives, declining cost of genome sequencing.

The genomic variant prioritization artificial intelligence (AI) market size is expected to see exponential growth in the next few years. It will grow to $5.68 billion in 2030 at a compound annual growth rate (CAGR) of 26.5%. The growth in the forecast period can be attributed to growing demand for precision medicine applications, increasing integration of AI in clinical genomics, expansion of population genomics programs, rising investment from pharmaceutical and biotechnology companies, development of scalable cloud-based genomic analytics platforms. Major trends in the forecast period include increasing adoption of AI-driven variant filtering platforms, growing integration of multi-omics data in prioritization models, expansion of clinical-grade interpretation and reporting tools, rising demand for automated genomic workflow management, development of explainable AI models for clinical decision support.

The increasing adoption of precision medicine is projected to drive the growth of the genomic variant prioritization artificial intelligence market in the future. Precision medicine involves designing personalized healthcare strategies by taking into account a patient’s genetic makeup, environment, and lifestyle. Its adoption is growing due to advances in genomics, which enable healthcare providers to analyze patients’ genetic profiles and develop targeted therapies that are more effective and have fewer side effects. Within research and clinical genomics workflows, genomic variant prioritization artificial intelligence supports precision medicine by analyzing and ranking genetic variants to identify those most likely to cause disease or impact treatment response, facilitating more precise therapeutic decisions. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022, reflecting the rapid growth of precision-medicine-driven drug development. Therefore, the increasing adoption of precision medicine is propelling the growth of the genomic variant prioritization artificial intelligence market.

Key companies operating in the genomic variant prioritization artificial intelligence market are focusing on developing innovative solutions such as phenotype-driven variant scoring to improve the accuracy and efficiency of identifying clinically relevant genetic variants for diagnosis and personalized treatment. Phenotype-driven variant scoring prioritizes genetic variants based on their likelihood of explaining a patient’s observed clinical traits or symptoms. For example, in October 2024, SeqOne S.A.S., a Switzerland-based clinical genomics software company, launched DiagAI Score, an explainable AI tool for genomic variant prioritization in whole-exome and whole-genome sequencing workflows. The tool generates a 0-100 score that ranks variants based on pathogenicity, phenotype matching via PhenoGenius, inheritance patterns, and quality metrics, reducing thousands of variants to a shortlist of fewer than 18 candidates with 95-96% sensitivity in disease-specific validation studies.

In July 2023, BioNTech SE, a Germany-based biotechnology company, acquired InstaDeep Ltd. for an undisclosed sum. This acquisition was intended to bolster BioNTech’s artificial intelligence and machine learning capabilities to accelerate drug discovery, genomic analysis, and target identification by integrating advanced AI platforms into its research workflow. InstaDeep Ltd. is a UK-based AI company that specializes in genomic variant prioritization.

Major companies operating in the genomic variant prioritization artificial intelligence (AI) market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., Tempus AI Inc., ​SOPHiA GENETICS SA, CENTOGENE N.V., Genomenon Inc., Deep Genomics Inc., Fabric Genomics Inc., Strand Life Sciences Pvt. Ltd., PierianDx Inc., Eurofins Scientific SE, Congenica Ltd., SeqOne Genomics SAS, Golden Helix Inc., PhenoTips Inc., Saphetor SA, Euformatics Ltd., enGenome s.r.l., Nostos Genomics Ltd., and Humanome.AI Inc.

North America was the largest region in the genomic variant prioritization artificial intelligence (AI) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic variant prioritization artificial intelligence (AI) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic variant prioritization artificial intelligence (AI) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genomic variant prioritization artificial intelligence (AI) market consists of revenues earned by entities by providing services such as pathogenicity prediction, variant ranking and prioritization, and integration with clinical guidelines. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic variant prioritization artificial intelligence (AI) market also includes sales of humanome, mutanome and emedgene. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genomic variant prioritization artificial intelligence (AI) applies advanced machine learning and AI techniques to identify and rank genetic variants most likely to be biologically significant or disease-causing from large genomic datasets. By integrating sequence features, predicted functional impact, population frequency, evolutionary conservation, and clinical or phenotypic data, AI models efficiently filter numerous variants to highlight those most relevant for diagnosis, research, or therapeutic decision-making.

The essential components of genomic variant prioritization artificial intelligence include software, hardware, and services. Software platforms apply AI algorithms to analyze genomic data and prioritize clinically relevant variants for diagnosis and research. Deployment models include on-premises, cloud-based, and hybrid systems. Applications include rare disease diagnosis, oncology and cancer genomics, pharmacogenomics, prenatal and reproductive health testing, population genomics, and infectious disease genomics, serving hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other end-users.

Tariffs on imported sequencing instruments, high performance computing servers, graphics processing accelerators, and specialized bioinformatics hardware are impacting the genomic variant prioritization AI market by increasing infrastructure and operational costs. Hardware segments such as HPC servers and GPU accelerators are particularly affected, especially in regions reliant on semiconductor imports including North America, Europe, and parts of Asia-Pacific. Research institutes and pharmaceutical companies may face higher deployment expenses for on-premise systems. However, tariffs are also encouraging domestic production of computing infrastructure and strengthening local AI software innovation, supporting long-term regional technological resilience.

The genomic variant prioritization artificial intelligence (AI) market research report is one of a series of new reports that provides genomic variant prioritization artificial intelligence (AI) market statistics, including genomic variant prioritization artificial intelligence (AI) industry global market size, regional shares, competitors with a genomic variant prioritization artificial intelligence (AI) market share, detailed genomic variant prioritization artificial intelligence (AI) market segments, market trends and opportunities, and any further data you may need to thrive in the genomic variant prioritization artificial intelligence (AI) industry. This genomic variant prioritization artificial intelligence (AI) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.